Lataa...
Harnessing the Power of Proteomics to Assess Drug Safety and Guide Clinical Trials
Assessing drug safety and efficacy is costly, and many promising candidates can present unwanted side effects. Can new developments in proteomic biomarkers help provide timely monitoring of efficacy and protect participant safety? In this issue, Williams et al. tackled this question with a retrospec...
Tallennettuna:
| Julkaisussa: | Circulation |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5842814/ https://ncbi.nlm.nih.gov/pubmed/29506994 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.032876 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|